UK pharmaceutical giant GSK (GSK.L) said Tuesday it agreed to acquire Nasdaq-listed oncology-focused biopharmaceutical company Nuvalent for $10.6 billion.
Under the deal, GSK will launch a tender offer to acquire Nuvalent's entire share capital at $124 per share in cash. GSK will fund the transaction primarily from new and existing debt facilities plush cash, with its aggregate investment estimated at $9.4 billion.
The planned acquisition gives GSK access to three lung cancer therapies: zidesamtinib, neladalkib and NVL-330. Both zidesamtinib and neladalkib are in late-stage studies for the treatment of non-small cell lung cancer, or NSCLC, and have received breakthrough therapy and orphan drug designations from the US Food and Drug Administration.
On the other hand, NVL-330, a potential HER2 inhibitor, is in phase I trials for HER2-altered NSCLC. The deal also covers Nuvalent's preclinical portfolio of multiple programs.
GSK Chief Executive Officer Luke Miels said the acquisition is "consistent with our approach to acquire assets that have clinically proven targets and meaningfully address an efficacy and/or tolerability gap."
Management expects the acquisition to contribute toward revenue growth from 2027 and to be incremental in achieving its sales goal of more than 40 billion pounds sterling by 2031.
With an expected deal closing in the third quarter, GSK anticipates low single-digit percentage dilution to core EPS for 2026, 2027 and 2028. However, it maintained its 2026 full-year guidance range of 7% to 9% growth in core operating profit and core EPS.
GSK shares were down 3% in early morning trading in London.



